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Abstract
Effective symptom management is a critical component of cancer treatment.
Computational tools that predict the course and severity of these symptoms have the
potential to assist oncology clinicians to personalize the patient’s treatment regimen
more efficiently and provide more aggressive and timely interventions. Three common
and inter-related symptoms in cancer patients are depression, anxiety, and sleep
disturbance. In this paper, we elaborate on the efficiency of Support Vector Regression
(SVR) and Non-linear Canonical Correlation Analysis by Neural Networks (n-CCA) to
predict the severity of the aforementioned symptoms between two different time points
during a cycle of chemotherapy (CTX). Our results demonstrate that these two
methods produced equivalent results for all three symptoms. These types of predictive
models can be used to identify high risk patients, educate patients about their symptom
experience, and improve the timing of pre-emptive and personalized symptom
management interventions.
Introduction 1
A growing body of evidence, [1–3] as well as clinical experience suggests that the 2
symptom experience of oncology patients is extremely variable. While some patients 3
experience very few symptoms, other patients undergoing the same treatment 4
experience multiple co-occurring symptoms that are severe and extremely distressing. 5
The clinical dilemma is how to identify these high risk patients prior to the initiation of 6
treatment, so that aggressive symptom management interventions can be initiated and 7
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deleterious outcomes can be avoided. The application of machine learning techniques to 8
develop algorithms to identify this high risk phenotype is the first step toward 9
individualized symptom management. 10
For this investigation, we applied machine learning techniques to develop an algorithm 11
that could identify patients with the highest severity scores for three common and 12
inter-related symptoms (i.e., depression, anxiety, sleep disturbance). Depression occurs 13
in up to 60% of cancer patients. [4] Between 35% and 53% of patients report anxiety 14
during cancer treatment [5] and 45% of patients experience both of these symptoms. [6] 15
Equally deleterious and linked to both depression and anxiety are complaints of sleep 16
disturbance in 30% to 50% of oncology patients. [7] All three symptoms are associated 17
with decrements in patients’ ability to function on a daily basis as well as on their 18
quality of life. Of note, according to a systematic review by Alvaro et al. [8] as 19
depression, anxiety and sleep disturbances are often grouped together, the treatment of 20
insomnia may prevent the development of anxiety and depressive disorders, and 21
vice-versa. Therefore, if we can predict the patients who are at a higher risk for these 22
symptoms, treatments can be initiated to manage these symptoms. In addition, these 23
efficient machine learning methods could be used to predict the severity other symptom 24
in patients with cancer, as well as in patients with other chronic medical conditions. 25
A large variety of machine learning techniques and algorithms can be used to predict 26
data by learning from previous observations. Choosing the most appropriate one for the 27
prediction of symptom severity is a challenging task. Several common problems exist 28
with this type of research including: small sample sizes; a significant number of missing 29
values; the large number of symptom assessment instruments with different 30
measurement scales; the different types of variables (e.g., categorical, ordinal, 31
continuous); and the subjective nature of symptom measurements, themselves. 32
Regression analysis is a common supervised machine learning method that can be used 33
to solve several biological and clinical problems. It is used to estimate the relationship 34
between a dependent variable (i.e., depression, anxiety, sleep disturbance) and one or 35
more independent variables (i.e., predictor(s)). Canonical Correlation Analysis is 36
another analytical method for exploring the relationships between two multivariate sets 37
of variables (e.g., set of variables from Time Point 1 (TP1) and Time Point 2 (TP2) of a 38
chemotherapry (CTX) cycle). In this study, we used Support Vector Regression (SVR) 39
with different kernels (i.e., linear, polynomial, radial sigma) and Non-linear Canonical 40
Correlation Analysis by Neural Networks (n-CCA) [9] to predict efficiently our 41
dependent variables (i.e., symptom severity scores of depression, anxiety and sleep 42
disturbance at TP2). The Multiple Imputation (MI) and Maximum Likelihood 43
Estimation (MLE) methods were applied in order to account for missing data. Similarly, 44
in order to accommodate the small sample size and avoid over-training, we applied a 45
10-times Repeated 10-fold Cross-validation (RCV) to our predictive models. To the best 46
of our knowledge, this study is the first of its kind in oncology symptom management to 47
applying n-CCA to predict the severity of three common symptoms in oncology patients. 48
An overview of our analysis is provided at Fig 1. 49
Our study is organized as follows: the Methods section provides the research 50
methodology along with all of the approaches used in the proposed model. The Results 51
section presents the comparison and evaluation of the aforementioned methods and 52
provides a summary of our results. 53
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Fig 1. Overview of our analytic approach to learn from data to predict future
symptoms of oncology patients
Materials and methods 54
Study Procedure 55
The study, from which our data was drawn, was approved by the Committee on Human 56
Research at the University of California, San Francisco and by the Institutional Review 57
Board at each of the study sites. From February 2010 to December 2013, all eligible 58
patients were approached by the research staff in the infusion unit to discuss 59
participation in the study. Written informed consent was obtained from all patients. 60
Depending on the length of their CTX cycles, patients completed questionnaires in their 61
homes, a total of six times over 2 cycles of CTX (i.e. prior to CTX administration 62
(Time 1 and 4), approximately 1 week after CTX administration (Time 2 and 5), 63
approximately 2 weeks after CTX administration (Time 3 and 6). For this study, which 64
is a secondary analysis of existing data, symptom data from the Time 1 and Time 2 65
assessment were analysed. Patients were asked to report on their symptom experience 66
for the previous week. Medical records were reviewed for disease and treatment 67
information. The methods for the parent study are described in fully detail in 68
previously published work. [2, 10,11] 69
Patients and Settings 70
We carried out a secondary analysis of existing data from this longitudinal study of the 71
symptom experience of oncology outpatients receiving CTX. The data used in this 72
study were obtained from the same dataset and relate to two different Time Points (i.e., 73
Time Point 1 (TP1, n1=1343; prior to CTX administration), Time Point 2 (TP2, 74
n2=1278; one week after CTX administration). 75
According to the study’s eligibility criteria: patients were ≥ 18 years of age; had a 76
diagnosis of breast, gastrointestinal (GI), gynecological (GYN), or lung cancer; had 77
received CTX within the preceding four weeks; were scheduled to receive at least two 78
additional cycles of CTX; were able to read, write, and understand English; and gave 79
written informed consent. Patients were recruited from two Comprehensive Cancer 80
Centers, one Veteran’s Affairs hospital, and four community-based oncology programs. 81
Instruments 82
The study instruments included a demographic questionnaire, the Karnofsky 83
Performance Status (KPS) scale, [12, 13] the Self-administered Comorbidity 84
Questionnaire (SCQ), [14] the Lee Fatigue Scale (LFS), [15] the Attentional Function 85
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Index (AFI), [16, 17] the General Sleep Disturbance Scale (GSDS), [18] the Center for 86
Epidemiological Studies-Depression Scale (CES-D), [19] and the Spielberg State-Trait 87
Anxiety Inventories (STAI-S and STAI-T). [20] 88
The demographic questionnaire provided information on age, marital status, years of 89
education, living arrangements, ethnicity, employment status and exercise. In addition 90
patients’ medical records were reviewed to obtain information on: body mass index 91
(BMI), hemoglobin (Hgb), type of cancer, number of metastatic sites, time since cancer 92
diagnosis, number or prior cancer treatments, and CTX cycle length. 93
To estimate changes in self-reported sleep disturbance, the GSDS was administered at 94
each time point. The GSDS consists of 21 items designed to assess the quality of sleep 95
in the past week. Each item was rated on a 0 (never) to 7 (every day) numeric rating 96
scale (NRS). The GSDS total score is the sum of the 21 items that can range from 0 (no 97
disturbance) to 147 (extreme sleep disturbance). A GSDS total score of ≥ 43 indicates 98
a significant level of sleep disturbance. [21] The GSDS has well-established validity and 99
reliability in shift workers, pregnant women, and patients with cancer and 100
HIV. [18,22,23] 101
The CES-D consists of 20 items selected to represent the major symptoms in the clinical 102
syndrome of depression. Scores can range from 0 to 60, with scores ≥ 16 indicating the 103
need for individuals to seek clinical evaluation for major depression. The CES-D has 104
well-established concurrent and construct validity. [19, 24,25] 105
The STAI-T and STAI-S inventories consist of 20 items each that are rated from 1 to 4. 106
The scores for each scale are summed and can range from 20 to 80. A higher score 107
indicates greater anxiety. The STAI-T measures an individual’s predisposition to 108
anxiety determined by his/her personality and estimates how a person feels generally. 109
The STAI-S measures an individual’s transitory emotional response to a stressful 110
situation. It evaluates the emotional response of worry, nervousness, tension, and 111
feelings of apprehension related to how people feel “right now” in a stressful situation. 112
The STAI-S and STAI-T inventories have well-established criteria and construct validity 113
and internal consistency reliability coefficients. [20, 26,27] 114
Data Analysis and Missing Data 115
Our data were collected from a cohort of oncology patients at two different Time Points, 116
Time Point 1 (i.e., TP1, nTP1=1343), Time Point 2 (i.e., TP2, nTP2=1278). By merging 117
the two different Time Points we created a new dataset of 1278 samples 118
(nTP1+TP2=1278). When we dropped the cases with at least one missing value in one of 119
their variables, we were left with 799 cases (65,1% of nTP1+TP2). To assess whether the 120
missing values were missing completely at random (MCAR), missing at random (MAR), 121
or missing not at random (MNAR) [28,29] we analysed our data with SPSS version 23 122
(IBM, Armonk, NY). Furthermore, in order to avoid the problem of biasing our analysis 123
by including only the complete cases, we used two different statistical approaches to 124
impute the missing values, namely, Multiple Imputation (MI) [29, 30] and the Maximum 125
Likelihood Estimation (MLE) [29,31]. 126
Multiple Imputation (MI) is a statistical approach to address the problem of the missing 127
observations that are frequently encountered in all types of epidemiological and clinical 128
studies. [32] It minimizes the uncertainty around our missing data by creating different 129
imputed data sets several times and integrating their results into a final, pooled result. 130
Fig 2 illustrates the MI procedure with an example. 131
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Fig 2. Multiple Imputation
During the first stage, MI creates multiple copies of the dataset, with the missing values 132
replaced by imputed values. These are sampled from their predictive distribution based 133
on the observed data. [30] MI must fully account for all uncertainty in predicting the 134
missing values by inserting appropriate variability into the multiple imputed values. 135
During the second stage, MI fits the model of interest to each of the imputed datasets. 136
The predicted estimations in each of the imputed datasets will differ because of the 137
variation introduced in the imputation of the missing values. These estimates are only 138
useful when averaged together to give the overall, pooled predicted associations. 139
Maximum Likelihood Estimation (MLE) is a common statistical method for estimating 140
the parameters of a specific model, by finding the parameter values that maximize the 141
likelihood of making the observations given these parameters. To elaborate more on this 142
topic, [29] suppose we try an experiment with N people where the probability of a 143
success for an individual is p and the probability of a failure is 1-p. If n people succeed 144
and N-n people fail, the likelihood is proportional to the product of the probabilities of 145
successes and failures or pn × (1− p)N−n. The value of p that maximizes the likelihood 146
is n/N or the overall proportion of success. In our analysis for example, maximum 147
likelihood produces the best estimate of the difference in the parameters between TP1 148
and TP2 that maximize the probability of observing the collected data. Unlike MI, MLE 149
provides a unique estimate of the missing values and it requires fewer decisions than MI. 150
To impute the missing values with the MI approach and the MLE, we used SPSS 151
version 23 (IBM, Armonk, NY). For the MI approach, we configured SPSS to 152
automatically choose an imputation method based on a scan of our data and produce 10 153
output datasets with imputed values. For the MLE approach, we configured SPSS 154
AMOS to use an independence model with a regression imputation and produce 1 155
output dataset with imputed values. 156
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Model Selection 157
To train and evaluate the performance of our different predictive models we divided our 158
dataset into two sub-sets: the Training (nTrain=1000) and Validation (nVal=278) 159
datasets. Cross-validation (CV) and Bootstrap are two common approaches that are 160
known to provide unbiased estimates for the test results of a predictive model. [33] 161
Cross-validation (CV) provides unbiased results but with a high error variance. On the 162
other hand, Bootstrap is known to have better performance in small samples, achieving 163
a small variance but requiring much heavier computation than CV. Combining the 164
strengths of both approaches, Repeated Cross-validation (RCV) appears to be a good 165
validation method for general use providing small bias with limited variability and a 166
reasonable computation load. [33] In fact, RCV is a repeated CV method, in which the 167
CV is repeated several times and then the average is taken. By the same rationale, 168
Boostrap .632 is designed to address the pessimistic bias of the standard Bootstrap 169
method, where the Bootstrap samples only contain approximately 63.2% of the unique 170
samples from the original dataset. [34, 35] 171
Before training our models on the data, we empirically compared all the aforementioned 172
validation methods on the original dataset before and after imputation for the missing 173
values. Based on the validation method results, we compared the two different types of 174
predictive models in our study with a 10-times and 10-fold RCV method. 175
We divided the original dataset with the missing values into a Training set of 176
nTrain=624 cases, and a Test set of nTest=175 cases. For the MI and MLE imputation 177
methods, we divided the datasets into a Train set of nTrain=1000 cases, and a Test set 178
of nTest=278 cases. As already mentioned, the MI produced 10 such datasets, with each 179
one of them having a total of n=1278 cases. 180
Support Vector Regression 181
Support Vector Machine (SVM) is a popular machine learning algorithm used to 182
analyze a variety of oncology data, [36–38] among many other applications. SVM 183
became increasingly popular because of its successful application for a different set of 184
problems (e.g. image recognition, text categorization, biosignals, 185
bioinformatics). [39–41] SVM works by mapping data to a high-dimensional feature 186
space so that data points can be categorized, even when the data are not otherwise 187
linearly separable. SVM manages this challenge with an operation called the kernel 188
trick. Through a variety of different kernel functions (e.g. Linear, Polynomial, Radial 189
Basis Function), SVM takes low dimensional input space and transforms it to a higher 190
dimensional space, thus converting non-separable problems to separable ones. With 191
SVM, the data are transformed in such a way that separators between the different 192
categories of the dataset can be found, optimized, and drawn. These separators are 193
called the Optimal Separation Hyperplanes (OSH). 194
Support Vector Regression (SVR) is an extension of the SVM classifier, estimating the 195
continuous function of a specific dataset. [42, 43] Similarly to SVM, SVR can model 196
complex non-linear relationships by using an appropriate kernel function which maps 197
the input data points onto a higher-dimensional feature space, transforming the 198
non-linear relationships into linear forms. The efficiency of the procedure is determined 199
by the kernel function’s parameters which do not depend on the dimensionality of 200
feature space. Both SVM and SVR depend on defining a loss function, called epsilon 201
intensive (), which ignores the errors that are situated within a certain distance of the 202
true value. Fig 3 shows an example of a non-linear regression function with its epsilon 203
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intensive band. In our study, we implemented all the different SVR models using R 204
version 3.3.0 and the Caret Package. [44] 205
Fig 3. Support Vector Regression
206
Non-linear Canonical Correlation Analysis by Neural Networks 207
In our study, we adapted the n-CCA which was introduced by Hsieh et al. in 2000. [9] 208
Our implementation was done with PyCharm Professional Edition 4.5, using Python 2.7 209
and the Scikit-Learn, Theano, and Lasagne libraries. [45–47] 210
Canonical Correlation Analysis (CCA) is a method to identify the linear combinations of 211
a set of variables X that have the highest correlations with linear combinations of a set 212
of variables Y. It estimates the correlated modes between the two data sets of variables 213
X (i.e, the data from TP1) and Y (i.e., the data from TP2) by solving the equations, 214
i) U = a ∗X, ii) V = b ∗ Y, (1)
while maximising the Pearson correlation between U and V. To achieve a better 215
performance in cases where the correlation between the two data sets is non-linear, the 216
equations can be modified to include a non-linear relationship. Hsieh et al. [9] have 217
introduced an implementation of n-CCA utilising three neural networks. For a more 218
in-depth mathematical description of the method, we refer to the original paper. [9] In 219
this paper, we describe the concepts of how the neural networks can be used to extract 220
the correlation between the two sets of variables (i.e., data from TP1 and TP2). 221
Fig 4 shows the architecture, as well as the training and validation stage, of our neural 222
network that implements n-CCA with our data from TP1 and TP2. Our model consists 223
of three networks which were trained separately. The first neural network is a 224
double-barrelled one (illustrated in the Training-(a) section of Fig 4). We called this 225
network the inner network and the other two the outer networks (shown in the 226
Training-(b) and Training-(c) sections of Fig 4). 227
The two barrels of the inner network (Training-(a) section of Fig 4) share the same 228
structure and take as input the data from TP1 and TP2 respectively. The input layer of 229
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Fig 4. n-CCA Training and Validation: (i) Training of the n-CCA model, (ii)
Validation of the n-CCA model
each barrel has n nodes, one for each feature of the data (nFeatures=29); see S1 Table for 230
a full list of these features). The hidden layer of each barrel contains 50 nodes, that 231
have the hyperbolic tangent function as their activation function. The output layer of 232
each barrel has only one node, producing an output U for the dataset from TP1 and an 233
output V for the data set from TP2 respectively. The aim of the training of the inner 234
network is to maximise the correlation between the two vectors, U and V. This aim is 235
achieved by using the negative Pearson coefficient [48] as the cost function which has to 236
be minimised. 237
The outer networks (Training-(b) and Training-(c) sections of Fig 4) are trained 238
separately, nevertheless they share the same structure. The input layer of each outer 239
network has only one node, taking as input the output (U and V respectively) of the 240
previous double-barrel inner network. The hidden layer of each of the outer networks 241
has 50 nodes with the hyperbolic tangent function as their activation function. The 242
output layer of each outer network produces the features that we need to predict. In our 243
study, we predicted the severity of three symptoms (i.e., sleep disturbance, depression, 244
anxiety). To predict them, each outer network learns the inverse function of each of the 245
barrels of the inner network and maps U and V, respectively, back to the features we 246
are interested to predict. The first outer network (Training-(b) section of Fig 4) maps U 247
back to predicted values of sleep disturbance, depression and anxiety for TP1 and the 248
second outer network (Training-(c) section of Fig 4) maps V back to predicted values of 249
sleep disturbance, depression and anxiety for TP2. The aim of the training of the outer 250
networks is to minimise the Mean Squared Error (MSE) between the predicted output 251
and the true values. This training phase consists of 100 epochs, during which we used a 252
10-times and 10-fold RCV. 253
When the training stage (Training section of Fig 4) is finished, we can use parts of the 254
model to predict TP2 data from new, unseen TP1 data (Validation section of Fig 4). 255
This process can be used either to validate the model or to predict the TP2 data, when 256
new patients are introduced into the model, where only the TP1 data are available. In 257
both cases, the TP1 data are fed into the left barrel of the inner network (Validation-(a) 258
section of Fig 4) to estimate the U vector for these data. By multiplying this output 259
with the Pearson coefficient R that was calculated during the training stage, we can 260
estimate the corresponding V vector. This information forms the input for the outer 261
right network (Validation-(c) section of Fig 4), which predicts the desired features for 262
the TP2 data. 263
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Comparison between SVR and n-CCA 264
To compare the performances of the SVR and n-CCA models we used their Root Mean 265
Square Error (RMSE) and Normalised Root Mean Square Error (NRMSE). The latter, 266
was calculated by dividing their RMSE with the mean of the measured values. 267
NRMSE =
RMSE
y¯
, (2)
Normalising the RMSE allows the comparison of models with different scales. Lower 268
values among these calculations indicate less residual variance for the predicted 269
outcomes. 270
In order to compare the results produced with the SVR and the n-CCA models we used 271
the Bland–Altman plot. [49, 50] The Bland-Altman plot is a graphical method to 272
compare two different measurement techniques. The difference between each technique’s 273
measurement for each case is plotted against the average of the other technique’s 274
measurement for the same case. The former is represented on the y-axis and the latter 275
on the x-axis. The full Bland-Altman plot draws these differences and averages for 276
every case in the test dataset. In our study, the mean difference and the mean difference 277
plus and minus 1.96 times the standard deviation of the differences are represented on 278
the Bland-Altman plot with horizontal lines (see Fig 5).
Fig 5. Bland - Atman plot of the SVR model with the polynomial function and the
n-CCA model on the dataset with Maximum Likelihood imputation
279
In order to evaluate the agreement between the real and predicted values, we compared 280
the mean, range, and kernel density plots of the results from the analyses on the dataset 281
with the MLE imputation. We compared the predictions of the SVR with polynomial 282
kernel and n-CCA models against the real values of our Test set (nTest=278 cases). 283
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Results 284
Data Analysis and Handling Missing Data 285
Our initial dataset that contained the data from both TP1 (prior to CTX 286
administration) and TP2 (one week after CTX administration; nTP1+TP2=1278), had 287
799 fully completed cases (65,1% of nTP1+TP2). The empty values in the dataset were 288
missing completely at random (Little’s MCAR test, p>0.05; Fig 5). These missing 289
values are due to missing responses from patients. In order to use the collected values of 290
all of our cases, we applied the MI [29,30] and MLE [29,31] to compensate for missing 291
values. 292
Fig 6. Missing Values Pattern (Little’s MCAR test, p>0.05)
Model Selection 293
As our validation method, we selected a 10-times and 10-fold RCV. Beforehand, we 294
compared the performance of this validation method with Bootstrap , Bootstrap .632 295
and 10-fold CV. As predictor variables we used the data collected from TP1 (for a full 296
description of these predictors see S1 Table). Moderate correlations were found among a 297
number of predictors (see Fig 7). Type of cancer was correlated with gender because 298
40.6 % (n=519) of the patients in our study had breast cancer. The number of prior 299
cancer treatments was correlated with time from patients’ initial cancer diagnosis. 300
Income was correlated with being married and living alone. KPS score [12,13] was 301
moderately correlated with sleep disturbance, attentional function, depression, and 302
morning fatigue. Finally regarding the symptoms collected in our dataset, moderate 303
correlations were found between sleep disturbance, anxiety, depression, attentional 304
function, morning energy, and morning fatigue. 305
PLOS 10/19
Fig 7. Correlation analysis of predictor variables
Our analytical models were implemented in all three types of datasets (i.e. the original 306
ones with the missing values, the ones imputed with MI, the ones imputed with MLE). 307
The performance of the models was evaluated based in the RMSE and the R-squared 308
(R2). Table 1 shows the performance of different SVR models for predicting depression 309
(CES-D) at TP2. 310
Based on these results (Table 1), we selected the 10-times and 10-fold RCV as our 311
preferred validation method to test and compare the remaining analyses. The best 312
overall performance for predicting CES-D at TP2 with SVR was implemented with the 313
polynomial kernel on the MI imputed dataset (RMSE=6.191, R2=0.644). This result 314
could be due to the method of imputation used in the latter dataset and the type of 315
kernel function that was used to construct the prediction model. All four validation 316
methods provided equivalent results with their best performance implemented on the 317
MI datasets. Bootstrap .632 combined with the polynomial kernel had the worst 318
performance on all three types of datasets (i.e. RMSE=9.954, R2=0.323). 319
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Table 1. Performance of Support Vector Regression (SVR) models for predicting
Depression (CES-D) at TP2
10-times
Repeated
10-fold CV
10-fold CV Bootstrap Bootstrap .632
Dataset Kernel RMSE R2 RMSE R2 RMSE R2 RMSE R2
Missing
data
Linear 6.484 0.589 6.484 0.589 6.484 0.589 6.484 0.589
Polynomial 6.435 0.592 6.435 0.592 6.436 0.592 8.268 0.416
Radial Sigma 6.475 0.591 6.470 0.592 6.473 0.591 6.752 0.559
Multiple
Imputation
Linear 6.201 0.644 6.201 0.644 6.201 0.644 6.201 0.644
Polynomial 6.191 0.644 6.191 0.644 6.193 0.644 8.121 0.517
Radial Sigma 6.401 0.628 6.387 0.630 6.389 0.630 6.512 0.587
Maximum
Likelihood
Linear 7.102 0.548 7.102 0.548 7.102 0.548 7.102 0.548
Polynomial 7.081 0.549 7.081 0.549 7.053 0.552 9.954 0.323
Radial Sigma 7.189 0.540 7.182 0.541 7.192 0.540 7.393 0.508
Comparison between SVR and n-CCA 320
To compare the different approaches used in our study, we applied three different SVR 321
and three n-CCA models to predict the severity of depression (CES-D), sleep 322
disturbance (GSDS), and state anxiety (STAI-S) at TP2. The SVR models were 323
implemented with three different kernels (i.e. Linear, Polynomial, Radial Sigma). All of 324
our models were tested on all three types of datasets. As predictors we used all the data 325
collected at TP1 (see S1 Table). 326
We compared the performance of the models based on their RMSE, their RMSE/mean 327
ratio (see Tables 2 & 3), and their differences in the Bland-Atman plots (Fig 5). In 328
general the SVR models provided better fitted models with lower prediction error. All 329
the models provided better results using the MI dataset. For the prediction of sleep 330
disturbance, the SVR with the polynomial kernel achieved a RMSE of 13.153 and a 331
RMSE/mean ratio of 0.209. For sleep disturbance, the n-CCA achieved a RMSE of 332
16.113 and R2 of 0.306. For the prediction of anxiety, the polynomial kernel achieved a 333
RMSE of 7.983 and a RMSE/mean ratio of 0.220. For anxiety the n-CCA achieved a 334
RMSE of 8.941 and a RMSE/mean ratio of 0.677. Finally, for the prediction of 335
depression, the polynomial kernel achieved a RMSE of 6.191 and a RMSE/mean ratio of 336
0.465. For depression, the n-CCA achieved a RMSE of 6.907 and a RMSE/mean ratio 337
of 0.221. 338
Table 2. Performance of Support Vector Regression (SVR) models for predicting Sleep
Disturbance (GSDS), Anxiety (STAI-S) and Depression (CES-D) at TP2
Sleep Dis-
turbance
Anxiety Depression
Dataset Kernel RMSE RMSE/mean RMSE RMSE/mean RMSE RMSE/mean
Missing
data
Linear 13.302 0.251 8.084 0.244 6.484 0.509
Polynomial 13.379 0.251 8.082 0.245 6.435 0.506
Radial Sigma 13.709 0.258 8.147 0.247 6.475 0.518
Multiple
Imputation
Linear 13.156 0.212 7.985 0.221 6.201 0.465
Polynomial 13.153 0.209 7.982 0.220 6.191 0.465
Radial Sigma 13.243 0.239 8.045 0.228 6.401 0.488
Maximum
Likelihood
Linear 13.316 0.248 8.583 0.256 7.102 0.537
Polynomial 13.331 0.246 8.476 0.251 7.081 0.536
Radial Sigma 13.836 0.256 8.625 0.258 7.189 0.556
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Table 3. Performance of n-CCA for predicting Sleep Disturbance (GSDS), Anxiety
(STAI-S) and Depression (CES-D) at TP2
Sleep Disturbance Anxiety Depression
Dataset RMSE RMSE/mean RMSE RMSE/mean RMSE RMSE/mean
Missing data 19.955 0.307 12.238 0.681 9.661 0.222
Multiple Im-
putation
16.113 0.306 8.941 0.677 6.907 0.221
Maximum
Likelihood
16.680 0.305 9.320 0.676 7.583 0.218
Regarding the discrepancies between the two types of measurements as shown on the 339
Bland-Atman plots (Fig 5), the mean differences in the measurements of all three 340
symptoms (i.e., sleep disturbance, anxiety, depression) were close to zero. Most of these 341
differences were between +1.96SD and -1.96SD from the mean difference, which suggests 342
a normal distribution. The two types of analysis (i.e., SVR with polynomial kernel and 343
n-CCA) show a moderate to high level of agreement between their measurements. 344
Comparison Between the Real and Predicted Values 345
For all three symptoms (i.e., sleep disturbance, anxiety, depression), the means of the 346
predicted values were very close to the means of the real values (Table 4). Regarding 347
their ranges, the ranges of the predicted values from the SVR models were much closer 348
to the ranges for the real values (Table 4). In general, the distributions of predicted 349
values, from both analytical models, were very similar to the distributions for real 350
values (Fig 8). n-CCA, as a Neural Network based algorithm, appears to be affected by 351
our relatively small sample size and the distribution of data on the edges of the 352
symptom scales. In general, it performed better where the data were denser (i.e., more 353
data). On the other hand, SVR with polynomial kernel appears to be less affected by 354
the aforementioned factors and provided predicted values with a high concordance with 355
the real values. 356
Table 4. Sleep Disturbance (GSDS), Anxiety (STAI-S) and Depression (CES-D) Real
values compared to the Predicted values with the SVR (polynomial kernel) and n-CCA
on the dataset with the Maximum Likelihood Estimation imputation
Symptoms
Real
Values
(mean)
Real
Values
(range)
SVR (polynomial kernel) n-CCA
Predicted
Values
(mean)
Predicted
Values
(range)
RMSE
RMSE
/
mean
Predicted
Values
(mean)
Predicted
Values
(range)
RMSE
RMSE
/
mean
Sleep Disturbance 54.796
7.000
-
105.000
54.089
20.044
-
100.214
13.331 0.246 54.600
38.427
-
86.368
16.680 0.305
Anxiety 34.481
20.000
-
76.000
33.749
19.495
-
74.236
8.476 0.251 34.865
24.895
-
57.583
9.320 0.267
Depression 14.119
0.000
-
49.000
13.205
0.097
-
49.110
7.081 0.536 13.792
4.578
-
33.338
7.583 0.550
Conclusion 357
This study is the first to use two different machine learning techniques to accurately 358
predict the severity of three common symptoms (i.e., sleep disturbance, anxiety, 359
depression) from prior to through one week following the administration of CTX. The 360
predictions were constructed using the features of the experimental dataset collected at 361
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Fig 8. Density plots of the Sleep Disturbance (GSDS), Anxiety (STAI-S) and
Depression (CES-D) Real values compared to the density plots of Predicted values with
the SVR (polynomial kernel) and n-CCA on the dataset with the Maximum Likelihood
Estimation imputation
the first Time Point. Using the SVR method, the differences between the real values 362
(i.e., symptom severity scores that the patients reported) and the predicted values were 363
not meaningful differences. Furthermore, we obtained fairly similar results with n-CCA 364
at the expense of having a smaller variance among the predicted values (i.e. higher ratio 365
of RMSE/mean in most cases). The results indicate that relatively similar findings were 366
obtained independent of the number of missing values or the imputation method used 367
to compensate for missing values in our dataset. The ability to predict the severity of 368
future symptoms in oncology patients will be a powerful tool for oncology clinicians. 369
Developing computational tools using machine learning techniques will assist clinicians 370
to risk profile patients and implement pre-emptive symptom management interventions. 371
Using this information, clinicians will be able to customize a patient’s treatment, 372
increase their tolerance for CTX, and improve their quality of life. Following replication, 373
these methods can be evaluated as a decision support tool to assist clinicians to improve 374
symptom management in patients receiving CTX. Finally, the approaches presented in 375
this paper, may be applicable to the same set of co-occurring symptoms in other chronic 376
medical conditions. 377
The optimization of the feature selection process was one of the limitations of our study. 378
Being an exploratory study for the performance of the aforementioned predictive 379
models, we focused on the construction of predictive models and their evaluation and 380
comparison. This effort was implemented through comparison of different imputation 381
techniques ( i.e. MI, MLE), validation (i.e. RCV, CV, Bootstrap, Bootstrap .632) and 382
evaluation methods (i.e. RMSE, Bland-Altman plot). Future work will focus on 383
defining an effective set of predictors, as well as pre-processing and enhancing the data 384
collection and representation to improve the efficiency of both of the SVR and the 385
n-CCA models. In addition, we will develop an incremental learning method with 386
additional time points and evaluate it on a similar dataset. [51] 387
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Supporting information
S1 Table. Predictor variables for the Support Vector Regression
(SVR) and the Non-linear Canonical Correlation Analysis by
Neural Networks models
Variables Type of variable Range
Age Continuous 19.9 - 90.72
Gender Nominal 1 - 3
Education Continuous 4 - 23
BMI Continuous 15.21 - 54.58
Ethnicity Nominal 0-3
Married Binary 0 - 1
Do you live alone Binary 0 - 1
Working Binary 0 - 1
Income Nominal 1 - 4
Caregiver to children Binary 0 - 1
Caregiver to adult Binary 0 - 1
Karnofsky Performance status Continuous 30 - 100
Self-administered comorbidity questionnaire (SCQ) score Nominal 0 - 21
Number of metastatic sites out of 9 Nominal 0 - 6
Type of cancer Nominal 1 - 4
Time of diagnosis to start of study in years Continuous 0.041 - 38.32
Number of prior treatments out of 9 Nominal 0 - 7
Hemoglobin (HgB1) Continuous 6.7 - 16.1
Exercise on a regular basis Binary 0 - 1
Cycle length Nominal 1 - 3
General Sleep Disturbance Scale Continuous 7-119
Morning fatigue measured as part of the Lee Fatigue Scale Continuous 0 - 9.84
Evening fatigue measured as part of the Lee Fatigue Scale Continuous 0 - 10
Morning energy measured as part of the Lee Fatigue Scale Continuous 0 - 10
Evening energy measured as part of the Lee Fatigue Scale Continuous 0 - 10
Attentional function index Continuous 0.54 - 10
Center for Epidemiological Studies-Depression Scale Continuous 0 - 56
State Anxiety Scale Continuous 20 - 80
Occurrence of pain Nominal 0 - 2
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